CAV Regimen (Cladribine Combined With Low Dose Ara-C and Venetoclax) Pretreatment Followed by Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Acute Leukemia: a Multi-center, Open-label and Prospective Clinical Trial

The First Affiliated Hospital of Soochow University1 site in 1 country30 target enrollmentOctober 1, 2021

ConditionsAcute Leukemia, Relapsed Acute Leukemia Refractory

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Acute Leukemia, Relapsed
Sponsor: The First Affiliated Hospital of Soochow University
Enrollment: 30
Locations: 1
Primary Endpoint: ORR (overall response rate)
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for acute leukemia (AL), relapsed or refractory (R/R) AL is still a big challenge. It is believed that decreased tumor burden before HSCT is a favorable factor contributing to the long-term survival of R/R AL patients and many kinds of bridging chemotherapy regimens were devised to kill leukemic cells before HSCT, there is still no consensus that which regimen is optimal. This study is to investigate the curative efficacy and safety of bridging CAV (cladribine combined with low dose Ara-C and venetoclax) regimens followed by HSCT treatment protocol for R/R AML.

Registry

clinicaltrials.gov

Start Date

October 1, 2021

End Date

November 17, 2024

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

The First Affiliated Hospital of Soochow University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with AL must meet one of the following criteria ：A or B. A: relapsed AL disease was defined as follows: (1) Reappearance of leukemic blasts in the peripheral blood after CR; or (2) detection of \>5% blasts in the bone marrow (BM) not attributable to another cause(e.g. regeneration after consolidation therapy); or (3) extramedullary relapse.
•B: refractory AL disease was defined as follows: (1) failure to achieve CR, CRh or CRi after two courses of intensive induction treatment. or (2) failure to achieve complete remission after one cycle of induction chemotherapy or a reduction in the number of blasts of less than 50% after one cycle of induction treatment, with residual blasts \>15%.
•patients without ≥grade 3 of cardiac, hepatic, pulmonary, or renal dysfunctions.
•sign informed consent voluntarily.
•Patients aged between 16 and 70 years old, male or female is permitted.
•ECOG performance status score less than
•The expected survival is longer than 3 months.

Exclusion Criteria

•With other malignant tumors.
•Patients received the treatment of cladribine or venetoclax.
•Patients received cardiac angioplasty or stent implantation.
•Active infections that are not under clinical control (bacteria or fungus or virus is included).
•Liver functions abnormalities (total bilirubin\>1.5 times the upper limit of the normal range, ALT/AST\>2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST\>1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine\>1.5 times the upper limit of normal value).
•Pregnant or nursing women.
•Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met.
•Patients participated in any other clinical trials 3 months prior to signing the informed consent.
•Patients not suitable for the study according to the investigator's assessment.